PharmaTelevision - AusBiotech: An Advancing Australia

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AusBiotech: An Advancing Australia

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Anna Lavelle, CEO of AusBiotech, about how the organisation performs its role as the interface between commerce, research scientists and the federal and state government agencies in Australia. Anna also outlines the progress the Australian biotechnology industry has made and discusses how AusBiotech plans to maintain that trend. The emergence of Australia as a significant player in the industry was reflected in the success of AusBiotech 2007 and Anna goes on to talk about the plans to further improve next year’s conference.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Role of AusBiotech .

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in Brisbane, Australia. On this show I have Anna Lavelle, who is the CEO of AusBiotech , welcome to the show Anna Lavelle.

Anna Lavelle:

Thank you Fintan it's great to see you again.

Fintan Walton:

Pleasure to see you to. Anna, you are the CEO of AusBiotech which is the countrywide Australian biotechnology organization, what is the role of AusBiotech ?

Anna Lavelle:

Well we have a complicated role, we are not for profit organization. We don't receive base funding from government, so in effect we are like a start up so we mirror the SMEs we mostly represent. We represent companies from the very small to the very large CSL being the largest Australian company and we also have pharmaceutical companies as our members. So we do advocacy, we interact with government, government relations, talk about legislation change, talk to the TGA help us remove any barriers to business that our SMEs are facing and also interact with the research community.

Fintan Walton:

Because in Australia you clearly you have the federal countries, you got the various states, state governments and in addition to that obviously you've got the Federal government itself, so you have this interface between the biotech, commercial biotech part of our industry here in Australia government and then just yourselves, how do you get that balance between those three from an AusBiotech perspective?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Anna Lavelle

CEO

Dr. Anna Lavelle was appointed inaugural CEO and Executive Director of AusBiotech in June 2005. She is also a member of the Pharmaceutical Industry Council. Previously Dr Anna Lavelle joined the Australian Red Cross Blood Service (ARCBS) in 1998 as Director responsible for Strategic Planning and Business Development. In 2002, Dr Anna Lavelle was appointed Director of Intellectual Capital, in which role she was responsible for management of the national research and development programme. Before joining ARCBS, Dr Anna Lavelle had commenced employment as an academic at Monash University, Melbourne, after having gained her PhD in Genetics from the University of Melbourne.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

AusBiotech

AusBiotech is Australia's Biotechnology Industry Organization, which represents over 2550 members and covers the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. The organization is dedicated to the development, growth and prosperity of the Australian biotechnology industry by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.